Nama's AI scorecard currently rates UroGen Pharma Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does URGN report earnings?

UroGen Pharma's next scheduled report is on Mar 2, 2027. Analysts expect EPS of $0.42.

What is the URGN price target?

The median analyst price target from 7 analysts is $60.00, with a range of $56.00 – $75.00.

Is URGN Shariah compliant?

Nama's AAOIFI-style screen reads UroGen Pharma as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

UroGen Pharma (URGN)

Healthcare · Biotechnology · NASDAQ

UroGen Pharma (URGN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.21B and a free-cash-flow yield of -13.7%. Over the most recent reported fiscal year, revenue grew 21.4%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +72.9% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-51.3%

How far the last close sits under the highest price of the past five years.

Market cap	$1.21B
Trailing P/E	—
Price / book	—
Price / sales	6.4
FCF yield	-13.7%
Dividend yield	—
Gross margin	90.8%
Operating margin	-35.3%
Net margin	-51.7%
Revenue growth (YoY)	+21.4%
Revenue growth (3-yr annual)	+19.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

URGN earnings

Next report: Mar 2, 2027 (Q4 2026, EPS estimate $0.42). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.03	$0.10	-130.0%	$89.00M
Q2 2026	Aug 5, 2026	-$0.28	-$0.26	-7.7%	$72.46M
Q1 2026	May 6, 2026	-$0.47	-$0.48	+2.1%	$50.96M
Q4 2025	Mar 2, 2026	-$0.53	-$0.51	-3.9%	$37.84M

URGN analyst price target

Median target $60.00 from 7 analysts, ranging $56.00 – $75.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live URGN data on Nama Insights →

URGN FAQ

Is URGN a buy?: Nama's AI scorecard currently rates UroGen Pharma Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does URGN report earnings?: UroGen Pharma's next scheduled report is on Mar 2, 2027. Analysts expect EPS of $0.42.
What is the URGN price target?: The median analyst price target from 7 analysts is $60.00, with a range of $56.00 – $75.00.
Is URGN Shariah compliant?: Nama's AAOIFI-style screen reads UroGen Pharma as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.